En español
NIDA

Menu

Publications

Quick Links

Montana Opioid Summary

Revised March 2019

Opioid-Related Overdose Deaths

Montana has one of the lowest age-adjusted rates of opioid-involved overdose deaths in the U.S. In 2017, 38 overdose deaths­­­ were reported–a rate of 3.6 deaths per 100,000 persons compared to the average national rate of 14.6 deaths per 100,000 persons. The number of prescription opioid-involved overdose deaths have steadily decreased overall from a peak of 75 cases in 2009 to 24 cases in 2017. Reports of overdose deaths involving synthetic opioids other than methadone (predominantly fentanyl) have been sporadic since 2008. The most recent data is from 2016 with 14 cases of overdose.

See textFigure 1. Number of overdose deaths involving opioids in Montana, by opioid category. Drug categories presented are not mutually exclusive, and deaths might have involved more than one substance. Source: CDC WONDER.

Opioid Pain Reliever Prescriptions

In 2017, Montana providers wrote 61.1 opioid prescriptions for every 100 persons (Figure 2). The average U.S. rate in the same year was 58.7 prescriptions per 100 persons or a total of 191,218,272 prescriptions (CDC).

The age-adjusted rate of prescription opioid-involved overdose deaths has declined overall since 2009 with 2.3 deaths per 100,000 persons reported in 2017.

See textFigure 2. Montana rate of overdose deaths involving prescription opioids and the opioid prescribing rate. Source: CDC and CDC WONDER.

Neonatal Abstinence Syndrome (NAS)

NAS or neonatal opioid withdrawal syndrome (NOWS) may occur when a pregnant woman uses drugs such as opioids during pregnancy. A recent national study revealed a fivefold increase in the incidence of NAS/NOWS between 2004 and 2014, from 1.5 cases per 1,000 hospital births to 8.0 cases per 1,000 hospital births. This is the equivalent of one baby born with symptoms of NAS/NOWS every 15 minutes in the United States. During the same period, hospital costs for NAS/NOWS births increased from $91 million to $563 million, after adjusting for inflation (Figure 3).

To date, there is no standard in NAS/NOWS provider and hospital coding practices (CDC). As a result, there is variability in trends and in the rate reported by states. The most recent data on the rate of babies born with NAS/NOWS in Montana is from 2014 and is based on state inpatient databases.  From 2012 to 2014, the rate of NAS/NOWS increased 78 percent from 4.4 cases per 1,000 hospital births to 7.8 cases per 1,000 hospital births (Healthcare Cost and Utilization Project).

See textFigure 3. NAS/NOWS Incidence rate and hospital costs for treatment in the United States. Source: T.N.A. Winkelman, et al., 2018.

HIV Prevalence and HIV Diagnoses Attributed to Injection Drug Use (IDU)

See text Figure 4. Montana: Estimated percent of male vs. female with new HIV diagnoses, by transmission category, 2016. Source: CDC and www.AIDSVU.org.
  • U.S. Incidence: In 2016, 9 percent (3,480) of the 39,589 new diagnoses of HIV in the United States were attributed to IDU. Among males, 6.3 percent (2,530) of new cases were transmitted via IDU or male-to-male contact and IDU. Among females, 2.3 percent (950) were transmitted via IDU (CDC).
  • U.S. Prevalence: In 2016, 991,447 Americans were living with a diagnosed HIV infection—a rate of 306.6 cases per 100,000 persons. Among males, 19.9 percent (150,4661) contracted HIV from IDU or male-to-male contact and IDU while 21 percent (50,154) of females were living with HIV attributed to IDU (CDC).
  • State Incidence: Of the new HIV cases in 2016, 17 occurred in Montana. Among males, 18.8 percent of new HIV cases were attributed to male-to-male contact and IDU. There were no new cases of HIV attributed to IDU among women (Figure 4) (AIDSVu).
  • State Prevalence: In 2015, an estimated 574 persons were living with a diagnosed HIV infection in Montana—a rate of 66 cases per 100,000 persons. Of those, 26.0 percent of cases among males were attributed to IDU or male-to-male contact and IDU. Among females, 34.1 percent were living with HIV attributed to IDU (AIDSVu).

Hepatitis C (HCV) Prevalence and HCV Diagnoses Attributed to Injection Drug Use1

  • U.S. Incidence: In 2016, there were an estimated 41,200 new cases of acute HCV2 (CDC). Among case reports that contain information about IDU, 68.6 percent indicated use of injection drugs (CDC).
  • U.S. Prevalence: An estimated 2.4 million Americans are living with HCV based on 2013-2016 annual averages (CDC).
  • State Incidence: There were approximately 20 new cases of acute HCV (1.9 per 100,000 persons) reported in Montana in 2016 (CDC).
  • State Prevalence: In Montana, there are an estimated 36,800 persons living with Hepatitis C (2013-2016 annual average), a rate of 900 cases per 100,000 persons (HepVu).

Additional Resources

NIH RePORTER FY2018 NIH-funded projects related to opioid use and use disorder in Montana: 0

Notes

  1. Not all states collect or report data on the incidence or prevalence of Hepatitis C or on how Hepatitis C is transmitted. When available, the data will be included.
  2. Actual acute cases are estimated to be 13.9 times the number of reported cases in any year.

This page was last updated March 2019

Get this Publication

Opioid Summaries by State

NIH HEAL (Helping to End Addiction Long-term) Initiative

New Opioid Overdose Materials for Patients

Easy-to-read Drug Facts

This Is NIDA: Opioids

This Is NIDA: Opioids

The National Institute on Drug Abuse's research-based, informative video series "This Is NIDA," addresses the topic of OPIOIDS.

美洲杯投注